126 related articles for article (PubMed ID: 23363643)
1. Pharmacodynamic comparisons for single loading doses of prasugrel (30 mg) and clopidogrel (600 mg) in healthy Korean volunteers.
Kim MH; Zhang HZ; Jung DK
Circ J; 2013; 77(5):1253-9. PubMed ID: 23363643
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
Small DS; Payne CD; Kothare P; Yuen E; Natanegara F; Teng Loh M; Jakubowski JA; Richard Lachno D; Li YG; Winters KJ; Farid NA; Ni L; Salazar DE; Tomlin M; Kelly R
Clin Ther; 2010 Feb; 32(2):365-79. PubMed ID: 20206794
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
Guo LZ; Kim MH; Jin CD; Lee JY; Yi SJ; Park MK; Cho YR; Park TH
Platelets; 2015; 26(6):563-9. PubMed ID: 25275429
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
5. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Angiolillo DJ; Badimon JJ; Saucedo JF; Frelinger AL; Michelson AD; Jakubowski JA; Zhu B; Ojeh CK; Baker BA; Effron MB
Eur Heart J; 2011 Apr; 32(7):838-46. PubMed ID: 21252171
[TBL] [Abstract][Full Text] [Related]
6. The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
Zhu B; Effron MB; Kulkarni MP; Li YG; Jakubowski JA; Miller DL; Baker BA; Luo J; Small DS; Winters KJ
J Cardiovasc Pharmacol; 2011 Mar; 57(3):317-24. PubMed ID: 21266916
[TBL] [Abstract][Full Text] [Related]
7. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
[TBL] [Abstract][Full Text] [Related]
8. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
[TBL] [Abstract][Full Text] [Related]
9. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
[TBL] [Abstract][Full Text] [Related]
10. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Payne CD; Li YG; Brandt JT; Jakubowski JA; Small DS; Farid NA; Salazar DE; Winters KJ
Platelets; 2008 Jun; 19(4):275-81. PubMed ID: 18569863
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Bernlochner I; Morath T; Brown PB; Zhou C; Baker BA; Gupta N; Jakubowski JA; Winters KJ; Schömig A; Kastrati A; Sibbing D
Platelets; 2013; 24(1):15-25. PubMed ID: 22372531
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
[TBL] [Abstract][Full Text] [Related]
13. Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial.
Ge J; Zhu J; Hong BK; Boonbaichaiyapruck S; Goh YS; Hou CJ; Pinton P
Curr Med Res Opin; 2010 Sep; 26(9):2077-85. PubMed ID: 20629598
[TBL] [Abstract][Full Text] [Related]
14. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
Montalescot G; Sideris G; Cohen R; Meuleman C; Bal dit Sollier C; Barthélémy O; Henry P; Lim P; Beygui F; Collet JP; Marshall D; Luo J; Petitjean H; Drouet L
Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936
[TBL] [Abstract][Full Text] [Related]
15. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Erlinge D; Gurbel PA; James S; Lindahl TL; Svensson P; Ten Berg JM; Foley DP; Wagner H; Brown PB; Luo J; Zhou C; Moser BA; Jakubowski JA; Small DS; Winters KJ; Angiolillo DJ
J Am Coll Cardiol; 2013 Aug; 62(7):577-83. PubMed ID: 23747759
[TBL] [Abstract][Full Text] [Related]
16. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Jernberg T; Payne CD; Winters KJ; Darstein C; Brandt JT; Jakubowski JA; Naganuma H; Siegbahn A; Wallentin L
Eur Heart J; 2006 May; 27(10):1166-73. PubMed ID: 16621870
[TBL] [Abstract][Full Text] [Related]
17. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Erlinge D; Ten Berg J; Foley D; Angiolillo DJ; Wagner H; Brown PB; Zhou C; Luo J; Jakubowski JA; Moser B; Small DS; Bergmeijer T; James S; Winters KJ
J Am Coll Cardiol; 2012 Nov; 60(20):2032-40. PubMed ID: 23083774
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Jakubowski JA; Li YG; Small DS; Payne CD; Tomlin ME; Luo J; Winters KJ
J Cardiovasc Pharmacol; 2010 Jul; 56(1):29-37. PubMed ID: 20386460
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
[TBL] [Abstract][Full Text] [Related]
20. Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.
Lee DH; Kim MH; Park TH; Park JS; Park K; Zhang HZ; Seo JM; Lee MS
Trials; 2013 Feb; 14():62. PubMed ID: 23448344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
